High variability of plasma drug concentrations in dual protease inhibitor regimens

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 986-990

  Guiard Schmid, Jean Baptiste ^a   Poirier, Jean Marie ^b   Meynard, Jean Luc ^c   Bonnard, Philippe ^a   Gbadoe, Ayi Hola ^a   Amiel, Corinne ^a   Calligaris, Frédérique ^c   Abraham, Bruno ^a   Pialoux, Gilles ^a   Girard, Pierre Marie ^c   Jaillon, Patrice ^b   Rozenbaum, Willy ^a  

^a HÔPITAL TENON   (France)

^b Saint Antoine University and Medical School   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 0037417018     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.986-990.2003     Document Type: Article

References (16)

1. Acosta, E. P. 2002. Pharmacokinetic enhancement of protease inhibitors. J. Acquir. Immune Defic. Syndr. 29(Suppl. 1):S11-S18.
2. Acosta, E. P., K. Henry, L. Baken, L. M. Page, and C. V. Fletcher. 1999. Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
3. Back, D. J., S. H. Khoo, S. E. Gibbons, and C. Merry. 2001. The role of therapeutic drug monitoring in treatment of HIV infection. Br. J. Clin. Pharmacol. 52(Suppl. 1):89S-96S.
4. Baede-van Dijk, P. A., P. W. Hugen, C. P. Verweij-van Wissen, P. P. Koopmans, D. M. Burger, and Y. A. Hekster. 2001. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 15:991-998.
5. Bardsley-Elliot, A., and G. L. Plosker. 2000. Nelfinavir: an update on its use in HIV infection. Drugs 59:581-620.
6. Dieleman, J. P., I. C. Gyssens, M. E. Van der Ende, S. de Marie, and D. M. Burger. 1999. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 13:473-478.
7. Gatti, G., A. Di Baggio, R. Casazza, C. De Pascalis, M. Bassetti, M. Cruciani, S. Vella, and D. Bassetti. 1999. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13:2083-2089.
8. Gieshke, R., B. Fotteler, N. Buss, and J. L. Steiner. 1999. Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin. Pharmacokinet. 37:75-86.
9. Hsu, A., G. R. Granneman, G. Gao, L. Carothers, A. Japour, T. El-Shourbagy, S. Dennis, J. Berg, K. Erdman, J. M. Leonard, and E. Sun. 1998. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. 22:2784-2791.
10. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
11. Moyle, G. J., and D. Back. 2001. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2:105-113.
12. Noble, S., and K. L. Goa. 2000. Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 60:1383-1410.
13. Pellegrin, I., D. Breilh, V. Birac, M. Deneyrolles, P. Mercie, A. Trylesinski, D. Neau, M. C. Saux, H. J. Fleury, and J. L. Pellegrin. 2001. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. Ther. Drug Monit. 23:332-340.
14. Pellegrin, I., D. Breilh, F. Montestruc, A. Caumont, I. Garrigue, P. Morlat, C. LeCamus, M. C. Saux, H. J. Fleury, and J. L. Pellegrin. 2002. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16:1331-1340.
15. Poirier, J. M., P. Robidou, and P. Jaillon. 2002. Simultaneous determination of the six HIV-protease inhibitors (amprenavir, indinavir, LPV, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. Ther. Drug Monit. 24:302-309.
16. Van Heeswijk, R. P. G., A. I. Veldkamp, R. M. W. Hoetelmans, J. W. Mulder, G. Schreij, A. Hsu, J. M. A. Lange, J. H. Beijnen, and P. L. Meenhorst. 1999. The steady state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-infected individuals. AIDS 13:95-99.